6-Methyl-1,2,3,5-tetrahydroimidazo<2,1-b>quinazolin-2-on | 58579-77-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-Methyl-1,2,3,5-tetrahydroimidazo<2,1-b>quinazolin-2-on
• 英文别名: 1,5-Dihydro-6-methylimidaz<2,1-b>chinazolin-2(3H)-on；6-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one；1,5-dihydro-6-methylimidazo[2,1-b]quinazolin-2(3H)-one；6-methyl-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one；BL-3459 free base；6-methyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one
• CAS: 58579-77-4
• 化学式: C₁₁H₁₁N₃O
• 分子量: 201.228
• InChiKey: QMIGUHOZYORBPK-UHFFFAOYSA-N

物化性质

• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  44.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-Methyl-1,2,3,5-tetrahydroimidazo<2,1-b>quinazolin-2-on 、 alkaline earth salt of/the/ methylsulfuric acid 在 potassium carbonate 作用下， 生成 1-Butyl-6-methyl-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one; hydrochloride
  参考文献：
  名称：

  Kienzle; Kaiser; Chodnekar, European Journal of Medicinal Chemistry, 1982, vol. 17, # 6, p. 547 - 556

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(2-Amino-6-methylbenzyl)-glycinethylester 以 乙醇 为溶剂， 以24%的产率得到6-Methyl-1,2,3,5-tetrahydroimidazo<2,1-b>quinazolin-2-on
  参考文献：
  名称：

  Process for the preparation of imidazo[2,1-b]quinazolinones

  摘要：

  已知心血管制剂的化学式为##STR1##其中R.sup.1和R.sup.2分别独立表示氢、(较低)烷基、(较低)烷氧基、(较低)烷硫基、三氟甲基、羟基、硝基、氯、溴或氟，通过将化合物##STR2##其中R.sup.1和R.sup.2如上所述，R.sup.3为氢、(较低)烷基或芳基，与化合物##STR3##其中X是如本文所述的离去基团，制备而成。

  公开号：

  US04208521A1

文献信息

• Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
  申请人：Glidden Paul F.

  公开号：US20090324710A1

  公开（公告）日：2009-12-31

  Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

  提供了预防和治疗方法，用于通过给予药剂，包括anagrelide和anagrelide衍生物，将循环血小板数量降至低于正常水平或低于正常水平，以抑制血管闭塞事件，包括栓塞。提供了包含这些药剂的方法和制药制剂。
• CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR
  申请人：Glidden Paul F.

  公开号：US20130022671A1

  公开（公告）日：2013-01-24

  Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

  提供了预防和治疗方法，以抑制血管闭塞事件，包括栓塞，通过给予药物，包括阿格列酯和阿格列酯衍生物，将循环血小板数量降低到低于正常水平或低于正常水平的水平。提供了包含这些药物的方法和制药制剂。
• 1,2,3,5-Tetrahydroimidazothienopyrimidin-2-ones, a process for their preparation and pharmaceutical compositions
  申请人：DAIICHI SEIYAKU CO., LTD.

  公开号：EP0008408A1

  公开（公告）日：1980-03-05

  A 1,2,3,5-tetrahydroimidazothienopyrimidin- 2- one represented by the formula: wherein one of Z1, Z2 and Z3 is a sulfur atom and the remaining two of Z1, Z1 and Z3 represent CH, R1 and R2 each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a phenyl group, a chlorine atom or, when taken together R1 and R2 represent an alkylene chain of 3 to 5 carbon atoms, and R3 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, and a pharmaceutically acceptable acid addition salt thereof, which exhibit an excellent blood platelet anti-aggregatory activity and are useful as anti-thrombotic agents. The invention also provides a process for the preparation of said compounds and a pharmaceutical composition comprising at least one of said compounds. I

  一种 1，2，3，5-四氢咪唑噻吩嘧啶-2-1，由式表示： 其中 Z1、Z2 和 Z3 中的一个是硫原子，Z1、Z1 和 Z3 中的其余两个代表 CH，R1 和 R2 各代表一个氢原子、一个具有 1 至 5 个碳原子的烷基、一个苯基、一个氯原子，或者当 R1 和 R2 合在一起时，代表一个具有 3 至 5 个碳原子的亚烷基链、和 R3 代表氢原子或具有 1 至 5 个碳原子的烷基，以及它们的药学上可接受的酸加成盐，它们表现出优异的血小板抗聚集活性，可用作抗血栓药物。本发明还提供了制备上述化合物的工艺以及包含至少一种上述化合物的药物组合物。I
• Methods and compositions for treating platelet-related disorders
  申请人：Hanson R. Stephen

  公开号：US20050228001A1

  公开（公告）日：2005-10-13

  Pharmaceutical preparations comprising one or more agents that reduce the number of circulating platelets to low normal or below normal levels formulated in a delivery system are provided. The pharmaceutical preparations are useful in the prophylactic and therapeutic treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by reducing the number of circulating platelets to low normal to below normal levels.

  本发明提供的药物制剂包含一种或多种可将循环血小板数量降至正常或低于正常水平的制剂，并配制在给药系统中。这些药物制剂可用于受试者的预防性和治疗性治疗，通过将循环血小板的数量降至正常或低于正常的低水平来抑制血管闭塞事件，包括栓塞。
• US3932407A
  申请人：——

  公开号：US3932407A

  公开（公告）日：1976-01-13